



Patent Claims: USA

1. The use of the compound of the formulae I and/or II



1



2

where compound 2 is present as such or in the form of a physiologically tolerable salt, for the preparation of pharmaceuticals for the treatment of rejection reactions of the organ recipient to the transplanted organ.

2. The use as claimed in claim 1, wherein the pharmaceutical is administered to the recipient or donor of the organ before, during and/or after transplantation.

3. The use as claimed in claim 1, wherein the pharmaceutical is employed for the treatment of hyperacute or acute rejection reactions.
4. The use as claimed in claim 1, wherein the pharmaceutical is employed for the treatment of chronic rejection reactions.
5. The use as claimed in claim 1, wherein the pharmaceutical is used in the transplantation of organs from one species to another species.
6. The use as claimed in claims 1, wherein the amount of allophilic or xenophilic antibodies is decreased.
7. The use as claimed in claim 1, wherein the pharmaceutical is employed in mammals, in particular the human.
8. The use as claimed in claim 1, wherein other active substances such as antiuricopathics, thrombocyte aggregation inhibitors, analgesics and steroidal or non-steroidal anti-inflammatories are employed.
9. A pharmaceutical for the treatment of rejection reactions of the organ recipient to the transplanted organ, which comprises an effective content of compound 1 and/or 2, it being possible for compound 2 to be present as such or in the form of a physiologically tolerable salt.
10. A process for the preparation of a pharmaceutical as claimed in claim 9 for the treatment of rejection reactions of the organ recipient to the transplanted organ, which comprises bringing compound 1 or 2 and/or a physiologically tolerable salt of

compound 2 into a suitable administration form using a physiologically acceptable excipient and other suitable active substances, additives or auxiliaries.